• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

    5/7/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email

    Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter

    First quarter 2025 highlights compared to Q1 2024:

    • Net revenue from continuing operations of $510.3 million, an increase of 5.7%
    • Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth
    • Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18
    • Adjusted Operating Income from continuing operations of $41.3 million
    • Adjusted Diluted EPS from continuing operations of $0.34
    • Raises fiscal 2025 outlook

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision," "we," "our," "us" or the "Company") today reported its financial results for the first quarter ended March 29, 2025.

    "Our first quarter results are a testament to the entire team's disciplined execution against the new strategic approach our leadership team began to implement last quarter," said Reade Fahs, National Vision's CEO. "We are seeing immediate impact from the initial wave of transformation actions with a return to mid-single digit comp performance and solid growth in bottom line results. The strength of these results reinforces our confidence in the long-term potential of our go-forward strategy and initiatives."

    Alex Wilkes, National Vision's President added, "The intentional, strategic shift to broaden our exposure to existing higher value customer segments coupled with our roadmap of future initiatives reinforces our confidence in our operational and financial growth, even amidst an increasingly uncertain environment. Looking ahead, we plan to continue introducing new lifestyle selling techniques, enhancing our branded frame assortment, and improving our digital experience to delight our customers and deliver the value they expect from us both in-store and online. All of this work will remain underpinned by our prudent approach to expense management, tariff mitigation efforts, and operational excellence to deliver improved profitability and sustainable value for shareholders."

    This release includes certain Non-GAAP Financial Measures that are not recognized under generally accepted accounting principles ("GAAP"). Please see "Non-GAAP Financial Measures" and "Reconciliation of Non-GAAP to GAAP Financial Measures" below for more information.

    During fiscal 2024, the Company ceased its Walmart and AC Lens operations and, accordingly, the condensed consolidated financial statements reflect the results of our former Legacy segment and the substantial majority of AC Lens operations as discontinued operations for all periods presented. Unless otherwise noted, amounts and disclosures in this press release relate to the Company's continuing operations.

    First Quarter 2025 Summary

    • Net revenue increased 5.7% to $510.3 million compared to the prior-year period and was primarily driven by Adjusted Comparable Store Sales Growth and growth from new store sales, partially offset by the effect of unearned revenue and the effect of closed stores. Net revenue includes a negative (1.5)% impact from the timing of unearned revenue in the current-year period compared with the prior-year period.
    • Comparable store sales growth was 4.1% and Adjusted Comparable Store Sales Growth was 5.5%, primarily due to higher average ticket, a slight increase in customer traffic and continued strength in the Company's managed care cohort.
    • The Company opened nine new America's Best stores, closed nine Fred Meyer stores and three America's Best stores, and ended the period with 1,237 stores. Overall, store count grew 3.0% from March 30, 2024 to March 29, 2025.
    • Costs applicable to revenue increased 4.9% to $205.2 million. As a percentage of net revenue, costs applicable to revenue decreased 30 basis points to 40.2%, mainly due to growth and improvement in product margins of eyeglass frames and lenses, and growth from other add-on sales, partially offset by a decrease in product margins of contact lenses and higher optometrist-related costs related to revenue growth.
    • SG&A increased 6.4% to $255.5 million. As a percentage of net revenue, SG&A increased 40 basis points to 50.1% of revenue. The primary drivers of SG&A growth were increases in stock-based compensation and cash compensation expenses related to revenue and profitability growth, partially offset by a non-recurring litigation settlement from the prior year, lower advertising investments and other expenses. Adjusted SG&A increased 4.6% to $241.1 million and represented 47.2% of net revenue, a decrease of 50 basis points driven by lower advertising investments, partially offset by higher cash compensation expenses, as discussed above.
    • Income from continuing operations increased to $14.2 million compared to $11.8 million in the same period in 2024. Income from continuing operations margin increased to 2.8% compared to 2.4% in the same period in 2024.
    • Diluted EPS from continuing operations was $0.18 compared to $0.15 in the same period in 2024. Adjusted Diluted EPS increased to $0.34 compared to $0.29 in the same period in 2024. The net change in margin on unearned revenue negatively impacted both Diluted EPS and Adjusted Diluted EPS by $(0.05).
    • Adjusted Operating Income increased 21.8% to $41.3 million compared with the same period of 2024. Adjusted Operating Margin increased to 8.1% compared with 7.0% for the same period in 2024. The net change in margin on unearned revenue negatively impacted income from continuing operations by $(4.1) million and Adjusted Operating Income by $(5.5) million.

    Balance Sheet and Cash Flow Highlights as of March 29, 2025

    • National Vision's cash balance was $80.0 million as of March 29, 2025. The Company had no borrowings under its $300.0 million first lien revolving credit facility, exclusive of letters of credit of $6.4 million.
    • Total debt was $346.1 million as of March 29, 2025, consisting of outstanding first lien term loans, 2.50% convertible senior notes due on May 15, 2025 ("2025 Notes") and finance lease obligations, net of unamortized discounts.

    Fiscal 2025 Outlook

    The Company is raising certain elements of its fiscal 2025 outlook for the 53 weeks ending January 3, 2026, as set forth below. The Company estimates the 53rd week of fiscal 2025 will contribute approximately $35 million to net revenue, and approximately $3 million to Adjusted Operating Income.

     

    Prior Fiscal 2025 Outlook

    Updated Fiscal 2025 Outlook

    New Stores

    30-35

    30-35

    Adjusted Comparable Store Sales Growth(1)(2)

    0.5% - 3.5%

    1.5% - 3.5%

    Net Revenue

    $1.901 billion - $1.955 billion

    $1.919 billion - $1.955 billion

    Adjusted Operating Income(2)

    $73 million - $88 million

    $81 million - $92 million

    Adjusted Diluted EPS(2)(3)

    $0.52 - $0.64

    $0.59 - $0.67

    Depreciation and Amortization(4)

    $93 million - $96 million

    $93 million - $96 million

    Interest(5)

    $17 million - $19 million

    $17 million - $19 million

    Tax Rate(6)

    27%

    27%

    Capital Expenditures

    $90 million - $95 million

    $90 million - $95 million

     

    1 For the 52 weeks ending December 27, 2025.

    2 Refer to "Non-GAAP Financial Measures" below for more information.

    3 Assumes approximately 79 million shares.

    4 Includes amortization of acquisition intangibles of approximately $0.7 million, which is excluded in the definition of Adjusted Operating Income.

    5 Before the impact of gains or losses on change in fair value of derivatives and charges related to debt discounts and deferred financing costs.

    6 Excluding the impact of vesting of restricted stock units and stock option exercises.

    The fiscal 2025 outlook information provided in this release includes Adjusted Operating Income and Adjusted Diluted EPS guidance. The Company is not able to reconcile these forward-looking non-GAAP measures to GAAP without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of certain items and unanticipated events, including taxes and non-recurring items, which would be included in GAAP results.

    The fiscal 2025 outlook is forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and based upon assumptions with respect to future decisions, which are subject to change. These uncertainties include, but are not limited to, dynamic market conditions, unexpected disruptions including additional regulatory actions impacting international trade such as tariffs, and other macroeconomic risks and uncertainties. Actual results may vary and those variations may be material. As such, the Company's results may not fall within the ranges contained in its fiscal 2025 outlook. The Company uses these forward-looking measures internally to assess and benchmark its results and strategic plans. See "Forward-Looking Statements" below.

    Conference Call Details

    The Company will host a conference call to discuss the first quarter 2025 financial results and fiscal-year 2025 guidance today, May 7, 2025, at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call will be available on the "Investors" section of the Company's website at www.nationalvision.com/investors, where presentation materials will be posted prior to the conference call. A replay of the audio webcast will also be archived on the "Investors" section of the Company's website.

    About National Vision Holdings, Inc.

    National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America's Best Contacts & Eyeglasses, Eyeglass World, and Vista Opticals inside select Fred Meyer stores and on select military bases, and an e-commerce website DiscountContacts.com, offering a variety of products and services for customers' eye care needs. For more information, please visit www.nationalvision.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2025 Outlook" as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company's strategic direction, market position, prospects including remote medicine and optometrist recruiting and retention initiatives, and future results. You can identify these forward-looking statements by the use of words such as "outlook," "guidance," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "projects," "predicts," "intends," "plans," "estimates," "anticipates" or variations of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Such factors include, but are not limited to, market volatility, an overall decline in the health of the economy, global macroeconomic conditions and other factors that may affect consumer spending or behavior; our ability to successfully implement our transformation initiatives, or anticipate the impact of important strategic initiatives; our ability to recruit and retain vision care professionals for in-store roles or to provide remote care offerings; our ability to compete in the highly competitive optical retail industry; the success of our marketing, advertising and promotional efforts; our ability to maintain, protect, and enhance the value of our owned brands; our ability to open and operate new stores (including as a result of store conversions) in a timely and cost-effective manner or to successfully enter new markets; our ability to increase sales in existing stores and to successfully reinvest in existing stores; our ability to successfully implement our pricing strategies; changes in the cost of inputs, and factors such as wage rate increases, inflation, cost increases, increases in the price of raw materials and energy prices; significant capital requirements to fund our expanding business including updating our Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM"), and other technological, systems and capabilities; the potential for our growth strategy to strain our existing resources and cause the performance of our existing stores to suffer; risks associated with leasing substantial amounts of space, including future increases in occupancy costs; our ability to successfully manage the distinct risks faced by our e-commerce and omni-channel business; our ability to retain our existing senior management team or attract qualified new personnel; seasonal fluctuations in our operating results and inventory levels fluctuate; the potential impacts of catastrophic events, including changing climate and weather patterns leading to severe weather and natural disasters; the potential for certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, or future drug development for the correction of vision-related problems to reduce the demand for our products; our ability to successfully manage our inventory balances and inventory shrinkage; the potential for the loss of, or disruption in the operations of, one or more of our distribution centers or optical laboratories, which would impact our ability to process and fulfill customer orders and deliver our products in a timely manner, or at all, or result in quality issues; the performance of our Host brands and our ability to maintain or extend our operating relationships with our Host partners; impacts resulting from the termination of our partnership with Walmart; our investments in technological innovators in the optical retail industry, including artificial intelligence; sustainability issues, including those related to climate change; our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors; risks associated with vendors from whom our products are sourced and our dependence on a limited number of suppliers; the impact of any significant failure, inadequacy, interruption or security breach affecting our information technology systems, or those of our vendors; our reliance on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues; our ability to comply with state, local and federal vision care and healthcare laws and regulations, as well as managed vision care laws and regulations; liability stemming from rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security and data protection; product liability, product recall or personal injury issues; our ability to comply with laws, regulations and enforcement activities or changes in statutory, regulatory, accounting and other legal requirements; the outcome of legal proceedings relating to our business operations; the protection and validity of our intellectual property; risks related to our indebtedness; changes in interest rates; restrictions in our credit agreement that limit our flexibility in operating our business; risks related to conversion of the 2025 Notes; and risks related to owning our common stock. Additional information about these and other factors that could cause National Vision's results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission ("SEC"), including our latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

    Non-GAAP Financial Measures

    To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "EBITDA," "Adjusted Operating Income," "Adjusted Operating Margin," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Adjusted Diluted EPS," "Adjusted Comparable Stores Sales Growth," "Adjusted SG&A," and "Adjusted SG&A Percent of Net Revenue." We believe EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, and Adjusted SG&A Percent of Net Revenue assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    To supplement the Company's comparable store sales growth presented in accordance with GAAP, the Company provides "Adjusted Comparable Store Sales Growth," which is a non-GAAP financial measure we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. Management uses Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Store Sales Growth to be meaningful.

    EBITDA: We define EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision, and depreciation and amortization.

    Adjusted Operating Income: We define Adjusted Operating Income from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net and income tax provision, further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM") implementation expenses, shareholder activism costs, severance and employee-related costs associated with organizational restructuring and certain other expenses.

    Adjusted Operating Margin: We define Adjusted Operating Margin from continuing operations as Adjusted Operating Income from continuing operations as a percentage of total net revenue.

    Adjusted EBITDA: We define Adjusted EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision and depreciation and amortization, further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses.

    Adjusted EBITDA Margin: We define Adjusted EBITDA Margin from continuing operations as Adjusted EBITDA from continuing operations as a percentage of total net revenue.

    Adjusted Diluted EPS: We define Adjusted Diluted EPS from continuing operations as diluted earnings (loss) per share, minus diluted earnings (loss) per share from discontinued operations, adjusted for the per share impact of stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, amortization of debt discounts and deferred financing costs of our term loan borrowings, amortization of the conversion feature and deferred financing costs related to our 2025 Notes when not required under U.S. GAAP to be added back for diluted earnings (loss) per share, derivative fair value adjustments, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses, and related tax effects.

    Adjusted SG&A: We define Adjusted SG&A from continuing operations as SG&A from continuing operations adjusted to exclude stock-based compensation expense, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expense, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses.

    Adjusted SG&A Percent of Net Revenue: We define Adjusted SG&A Percent of Net Revenue from continuing operations as Adjusted SG&A from continuing operations as a percentage of total net revenue.

    Adjusted Comparable Store Sales Growth: We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any reporting period, compared to sales recorded by the comparable store base in the prior reporting period, which we calculate as follows: (i) sales are recorded on a cash basis (i.e. when the order is placed and paid for or submitted to a managed care payor, compared to when the order is delivered), utilizing cash basis point of sale information from stores; (ii) stores are added to the calculation during the 13th full fiscal month following the store's opening; (iii) closed stores are removed from the calculation for time periods that are not comparable; (iv) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (v) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers.

    EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, Adjusted SG&A Percent of Net Revenue and Adjusted Comparable Store Sales Growth are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or the ratio of net income to net revenue as a measure of financial performance, SG&A, the ratio of SG&A to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, comparable store sales growth as a measure of operating performance, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Please see "Reconciliation of Non-GAAP to GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures.

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets (Unaudited)

     

    In Thousands, Except Par Value

    As of

    March 29, 2025

     

    As of

    December 28, 2024

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    80,024

     

     

    $

    73,948

     

    Accounts receivable, net

     

    53,169

     

     

     

    49,938

     

    Inventories, net

     

    88,571

     

     

     

    93,918

     

    Prepaid expenses and other current assets

     

    32,360

     

     

     

    32,024

     

    Total current assets

     

    254,124

     

     

     

    249,828

     

     

     

     

     

    Noncurrent assets:

     

     

     

    Property and equipment, net

     

    357,738

     

     

     

    362,175

     

    Goodwill

     

    698,305

     

     

     

    698,305

     

    Trademarks and trade names

     

    240,547

     

     

     

    240,547

     

    Other intangible assets, net

     

    8,087

     

     

     

    8,269

     

    Right of use assets

     

    402,660

     

     

     

    408,589

     

    Other assets

     

    48,891

     

     

     

    40,058

     

    Total noncurrent assets

     

    1,756,228

     

     

     

    1,757,943

     

    Total assets

    $

    2,010,352

     

     

    $

    2,007,771

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    36,661

     

     

    $

    53,643

     

    Other payables and accrued expenses

     

    115,070

     

     

     

    109,036

     

    Unearned revenue

     

    49,953

     

     

     

    42,002

     

    Deferred revenue

     

    64,331

     

     

     

    62,507

     

    Current maturities of long-term debt and finance lease obligations

     

    101,473

     

     

     

    101,392

     

    Current operating lease obligations

     

    100,721

     

     

     

    99,694

     

    Total current liabilities

     

    468,209

     

     

     

    468,274

     

     

     

     

     

    Noncurrent liabilities:

     

     

     

    Long-term debt and finance lease obligations, less current portion and debt discount

     

    244,652

     

     

     

    248,610

     

    Noncurrent operating lease obligations

     

    358,267

     

     

     

    366,335

     

    Deferred revenue

     

    22,565

     

     

     

    22,082

     

    Other liabilities

     

    8,373

     

     

     

    8,228

     

    Deferred income taxes, net

     

    72,126

     

     

     

    77,909

     

    Total non-current liabilities

     

    705,983

     

     

     

    723,164

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, $0.01 par value; 200,000 shares authorized; 85,847 and 85,444 shares issued as of March 29, 2025 and December 28, 2024, respectively; 79,050 and 78,775 shares outstanding as of March 29, 2025 and December 28, 2024, respectively

     

    858

     

     

     

    854

     

    Additional paid-in capital

     

    814,309

     

     

     

    807,048

     

    Retained earnings

     

    240,303

     

     

     

    226,117

     

    Treasury stock, at cost; 6,797 and 6,669 shares as of March 29, 2025 and December 28, 2024, respectively

     

    (219,310

    )

     

     

    (217,686

    )

    Total stockholders' equity

     

    836,160

     

     

     

    816,333

     

    Total liabilities and stockholders' equity

    $

    2,010,352

     

     

    $

    2,007,771

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

     

     

    Three Months Ended

    In thousands, except per share amounts

    March 29, 2025

     

    March 30, 2024

    Revenue:

     

     

     

    Net product sales

    $

    412,765

     

    $

    388,083

     

    Net sales of services and plans

     

    97,559

     

     

    94,711

     

    Total net revenue

     

    510,324

     

     

    482,794

     

    Costs applicable to revenue (exclusive of depreciation and amortization):

     

     

     

    Products

     

    116,914

     

     

    113,204

     

    Services and plans

     

    88,276

     

     

    82,342

     

    Total costs applicable to revenue

     

    205,190

     

     

    195,546

     

    Operating expenses:

     

     

     

    Selling, general and administrative expenses

     

    255,532

     

     

    240,128

     

    Depreciation and amortization

     

    22,963

     

     

    23,221

     

    Asset impairment

     

    502

     

     

    456

     

    Other expense (income), net

     

    —

     

     

    1

     

    Total operating expenses

     

    278,997

     

     

    263,806

     

    Income from operations

     

    26,137

     

     

    23,442

     

    Interest expense, net

     

    4,572

     

     

    4,256

     

    Earnings from continuing operations before income taxes

     

    21,565

     

     

    19,186

     

    Income tax provision

     

    7,379

     

     

    7,433

     

    Income from continuing operations

     

    14,186

     

     

    11,753

     

    Loss from discontinued operations, net of tax

     

    —

     

     

    (68

    )

    Net income

    $

    14,186

     

    $

    11,685

     

     

     

     

     

    Basic earnings (loss) per share:

     

     

     

    Continuing operations

    $

    0.18

     

    $

    0.15

     

    Discontinued operations

    $

    —

     

    $

    (0.00

    )

    Total

    $

    0.18

     

    $

    0.15

     

    Diluted earnings (loss) per share:

     

     

     

    Continuing operations

    $

    0.18

     

    $

    0.15

     

    Discontinued operations

    $

    —

     

    $

    (0.00

    )

    Total

    $

    0.18

     

    $

    0.15

     

     

     

     

     

    Weighted average shares outstanding:

     

     

     

    Basic

     

    78,858

     

     

    78,384

     

    Diluted

     

    79,259

     

     

    78,826

     

     

     

     

     

    Comprehensive income:

     

     

     

    Net income

    $

    14,186

     

    $

    11,685

     

    Unrealized gain on hedge instruments

     

    —

     

     

    254

     

    Tax provision of unrealized gain on hedge instruments

     

    —

     

     

    64

     

    Comprehensive income

    $

    14,186

     

    $

    11,875

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Cash Flows (Unaudited)

     

     

    Three Months Ended

    In Thousands

    March 29, 2025

     

    March 30, 2024

    Cash flows from operating activities:

     

     

     

    Net income

    $

    14,186

     

     

    $

    11,685

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    22,963

     

     

     

    24,181

     

    Amortization of debt discount and deferred financing costs

     

    367

     

     

     

    629

     

    Amortization of cloud computing implementation costs

     

    2,157

     

     

     

    1,132

     

    Asset impairment

     

    502

     

     

     

    456

     

    Deferred income tax expense (benefit)

     

    (5,783

    )

     

     

    (7,952

    )

    Stock-based compensation expense

     

    7,029

     

     

     

    2,465

     

    (Gains) on change in fair value of derivatives

     

    —

     

     

     

    (190

    )

    Inventory adjustments

     

    1,039

     

     

     

    1,350

     

    Other

     

    (26

    )

     

     

    (303

    )

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (3,341

    )

     

     

    12,287

     

    Inventories

     

    4,309

     

     

     

    (6

    )

    Operating lease right of use assets and lease liabilities

     

    (666

    )

     

     

    (705

    )

    Other assets

     

    (10,922

    )

     

     

    1,401

     

    Accounts payable

     

    (16,982

    )

     

     

    (6,759

    )

    Deferred and unearned revenue

     

    10,258

     

     

     

    (988

    )

    Other liabilities

     

    7,149

     

     

     

    (14,696

    )

    Net cash provided by operating activities

     

    32,239

     

     

     

    23,987

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (20,225

    )

     

     

    (20,014

    )

    Other

     

    —

     

     

     

    1,805

     

    Net cash used for investing activities

     

    (20,225

    )

     

     

    (18,209

    )

    Cash flows from financing activities:

     

     

     

    Repayments on long-term debt

     

    (3,313

    )

     

     

    (1,875

    )

    Proceeds from issuance of common stock

     

    265

     

     

     

    320

     

    Purchase of treasury stock

     

    (1,624

    )

     

     

    (2,721

    )

    Payments on finance lease obligations

     

    (732

    )

     

     

    (897

    )

    Net cash used for financing activities

     

    (5,404

    )

     

     

    (5,173

    )

    Net change in cash, cash equivalents and restricted cash

     

    6,610

     

     

     

    605

     

    Cash, cash equivalents and restricted cash, beginning of year

     

    75,237

     

     

     

    151,027

     

    Cash, cash equivalents and restricted cash, end of period (i)

    $

    81,847

     

     

    $

    151,632

     

     

    (i) Cash balance includes restricted cash of $1.8 million and $1.6 million for the three months ended March 29, 2025 and March 30, 2024, respectively, that are not reflected in cash and cash equivalents shown on the Condensed Consolidated Balance Sheets.

    National Vision Holdings, Inc. and Subsidiaries

    Reconciliation of Non-GAAP to GAAP Financial Measures (Unaudited)

     

    Reconciliation of Adjusted Operating Income from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

    In thousands

    March 29, 2025

     

    March 30, 2024

    Net income

    $

    14,186

     

     

    $

    11,685

     

    Income (loss) from discontinued operations, net of tax

     

    —

     

     

     

    (68

    )

    Income from continuing operations

     

    14,186

     

     

     

    11,753

     

    Interest expense, net

     

    4,572

     

     

     

    4,256

     

    Income tax provision

     

    7,379

     

     

     

    7,433

     

    Stock-based compensation expense (a)

     

    7,029

     

     

     

    2,414

     

    Asset impairment (b)

     

    502

     

     

     

    456

     

    Litigation settlement (c)

     

    —

     

     

     

    4,450

     

    Amortization of acquisition intangibles (d)

     

    169

     

     

     

    381

     

    ERP and CRM implementation expenses (g)

     

    2,315

     

     

     

    516

     

    Other (h)

     

    5,123

     

     

     

    2,235

     

    Adjusted Operating Income from continuing operations

    $

    41,275

     

     

    $

    33,894

     

     

     

     

     

    Income from continuing operations margin

     

    2.8

    %

     

     

    2.4

    %

    Adjusted Operating Margin from continuing operations

     

    8.1

    %

     

     

    7.0

    %

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

    Reconciliation of EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

    In thousands

    March 29, 2025

     

    March 30, 2024

    Net income

    $

    14,186

     

     

    $

    11,685

     

    Income (loss) from discontinued operations, net of tax

     

    —

     

     

     

    (68

    )

    Income from continuing operations

     

    14,186

     

     

     

    11,753

     

    Interest expense, net

     

    4,572

     

     

     

    4,256

     

    Income tax provision

     

    7,379

     

     

     

    7,433

     

    Depreciation and amortization

     

    22,963

     

     

     

    23,221

     

    EBITDA from continuing operations

     

    49,100

     

     

     

    46,663

     

     

     

     

     

    Stock-based compensation expense (a)

     

    7,029

     

     

     

    2,414

     

    Asset impairment (b)

     

    502

     

     

     

    456

     

    Litigation settlement (c)

     

    —

     

     

     

    4,450

     

    ERP and CRM implementation expenses (g)

     

    2,315

     

     

     

    516

     

    Other (h)

     

    5,123

     

     

     

    2,235

     

    Adjusted EBITDA from continuing operations

    $

    64,069

     

     

    $

    56,734

     

     

     

     

     

    Income from continuing operations margin

     

    2.8

    %

     

     

    2.4

    %

    Adjusted EBITDA Margin from continuing operations

     

    12.6

    %

     

     

    11.8

    %

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

    Reconciliation of Adjusted Diluted EPS from Continuing Operations to Diluted EPS

     

    Three Months Ended

    Shares in thousands, except per share amounts

    March 29, 2025

     

    March 30, 2024

    Diluted EPS

    $

    0.18

     

     

    $

    0.15

     

    Diluted EPS from discontinued operations

     

    —

     

     

     

    (0.00

    )

    Diluted EPS from continuing operations

    $

    0.18

     

     

    $

    0.15

     

    Stock-based compensation expense (a)

     

    0.09

     

     

     

    0.03

     

    Asset impairment (b)

     

    0.01

     

     

     

    0.01

     

    Litigation settlement (c)

     

    —

     

     

     

    0.06

     

    Amortization of acquisition intangibles (d)

     

    0.00

     

     

     

    0.00

     

    Amortization of debt discount and deferred financing costs (e)

     

    0.00

     

     

     

    0.01

     

    Derivatives fair value adjustments (f)

     

    —

     

     

     

    0.03

     

    ERP and CRM implementation expenses (g)

     

    0.03

     

     

     

    0.01

     

    Other (h)

     

    0.06

     

     

     

    0.02

     

    Tax effects (i)

     

    (0.03

    )

     

     

    (0.03

    )

    Adjusted Diluted EPS from continuing operations

    $

    0.34

     

     

    $

    0.29

     

     

     

     

     

    Weighted average diluted shares outstanding

     

    79,259

     

     

     

    78,826

     

     

     

     

     

    Reconciliation of Adjusted SG&A from Continuing Operations to SG&A from Continuing Operations

     

    Three Months Ended

    In thousands

    March 29, 2025

     

    March 30, 2024

    SG&A from continuing operations

    $

    255,532

     

     

    $

    240,128

     

    Stock-based compensation expense (a)

     

    7,029

     

     

     

    2,414

     

    Litigation settlement (c)

     

    —

     

     

     

    4,450

     

    ERP and CRM implementation expenses (g)

     

    2,315

     

     

     

    516

     

    Other (h)

     

    5,123

     

     

     

    2,235

     

    Adjusted SG&A from continuing operations

    $

    241,065

     

     

    $

    230,513

     

     

     

     

     

    SG&A from continuing operations Percent of Net Revenue

     

    50.1

    %

     

     

    49.7

    %

    Adjusted SG&A from continuing operations Percent of Net Revenue

     

    47.2

    %

     

     

    47.7

    %

    Note: Percentages reflect line item as a percentage of total net revenue.

    (a)

    Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.

    (b)

    Reflects write-off related to non-cash impairment charges of long-lived assets, primarily impairment of property, equipment and lease-related assets on closed or underperforming stores.

    (c)

    Expenses associated with settlement of certain litigation.

    (d)

    Amortization of the increase in carrying values of finite-lived intangible assets resulting from the application of purchase accounting following the acquisition of the Company by affiliates of KKR & Co. Inc.

    (e)

    Amortization of deferred financing costs and other non-cash charges related to our debt. We adjust for amortization of deferred financing costs related to the 2025 Notes only when adjustment for these costs is not required in the calculation of diluted earnings per share under U.S. GAAP.

    (f)

    The adjustments for the derivative fair value (gains) and losses have the effect of adjusting the (gain) or loss for changes in the fair value of derivative instruments and amortization of AOCL for derivatives not designated as accounting hedges. This results in reflecting derivative (gains) and losses within Adjusted Diluted EPS during the period the derivative is settled.

    (g)

    Costs related to the Company's ERP and CRM implementation.

    (h)

    Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS, Adjusted EBITDA and Adjusted SG&A), which are primarily related to shareholder activism costs of $2.1 million and severance and employee-related costs associated with organizational restructuring of $2.1 million for the three months ended March 29, 2025, costs associated with the digitization of paper-based records of $1.8 million for the three months ended March 30, 2024, and other expenses and adjustments. Adjusted Diluted EPS is also adjusted to include debt issuance costs.

    (i)

    Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates, including tax expense (benefit) from stock-based compensation.

    Reconciliation of Adjusted Comparable Store Sales Growth from Continuing Operations to Total Comparable Store Sales Growth from Continuing Operations

     

    Comparable store sales growth from continuing operations (a)

     

    Three Months Ended March 29, 2025

     

    Three Months Ended March 30, 2024

     

    2025 Outlook (b)

    Owned & Host segment

     

     

     

     

     

    America's Best

    5.9 %

     

    1.2 %

     

     

    Eyeglass World

    3.1 %

     

    (5.0) %

     

     

    Military

    1.7 %

     

    (1.4) %

     

     

    Fred Meyer

    1.6 %

     

    (5.9) %

     

     

     

     

     

     

     

     

    Total comparable store sales growth from continuing operations

    4.1 %

     

    1.4 %

     

    2.0% - 4.0%

    Adjustments for effects of: (b)

     

     

     

     

     

    Unearned & deferred revenue

    1.4 %

     

    (1.0) %

     

     

    Adjusted Comparable Store Sales Growth from continuing operations

    5.5 %

     

    0.4 %

     

    1.5% - 3.5%

    (a)

    Total comparable store sales from continuing operations is calculated based on consolidated net revenue from continuing operations excluding the impact of (i) other segments revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on cash basis revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 16. "Segment Reporting" in our Annual Report on Form 10-K for the period ended December 28, 2024.

    (b)

    Adjusted Comparable Store Sales Growth from continuing operations includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in the changes from total comparable store sales growth from continuing operations based on consolidated net revenue from continuing operations; with respect to the Company's 2025 Outlook, Adjusted Comparable Store Sales Growth includes an estimated 0.5% decrease for the effect of deferred and unearned revenue as if such revenues were earned at the point of sale.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507316125/en/

    Investor contact:

    [email protected]

    National Vision Holdings, Inc.

    Tamara Gonzalez

    ICR, Inc.

    Caitlin Churchill

    Media contact:

    [email protected]

    Get the next $EYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    1/17/2023Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    See more
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

      Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

      3/17/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Christopher Laden as Chief Financial Officer

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of Christopher Laden as Chief Financial Officer, effective March 31, 2025. He will succeed Melissa Rasmussen who, as previously announced, will step down from the Company, effective March 3, 2025. "We are thrilled to welcome Chris to National Vision. He has a proven track record of successfully developing finance organizations into strong cross-functional business partners by focusing on accountability, employee development, and driving efficiencies through the use of digitization. His experience in both the service and optical industries will be instrumental as we move forward

      2/26/25 5:59:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $EYE
    Financials

    Live finance-specific insights

    See more

    $EYE
    SEC Filings

    See more
    • Chief Legal & Strategy Officer Brandman Jared converted options into 1,889 shares and covered exercise/tax liability with 562 shares, increasing direct ownership by 3% to 44,705 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/30/25 4:27:11 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Brand & Mktg Officer Vandette Joseph converted options into 1,831 shares and covered exercise/tax liability with 545 shares, increasing direct ownership by 9% to 15,940 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/14/25 4:43:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Laden Christopher

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/1/25 4:17:22 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision downgraded by Goldman with a new price target

      Goldman downgraded National Vision from Buy to Neutral and set a new price target of $16.00 from $25.00 previously

      10/17/23 7:19:16 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

      Strong Fourth Quarter Results Reflect Successful Execution on Store-Level Transformation Initiatives Introduced Targeted Initiatives to Broaden Appeal and Expand Customer Base Actions Taken to Reduce Costs and Strengthen Profitability Fourth quarter 2024 highlights: Net revenue from continuing operations of $437.3 million, an increase of 3.9% as compared to Q4 2023 Comparable store sales growth of 2.6% and Adjusted Comparable Store Sales Growth of 1.5% as compared to Q4 2023 Net loss from continuing operations of $(29.4) million, Diluted EPS from continuing operations of $(0.37) Adjusted Operating Income from continuing operations increased to $3.2 million from $(2.7) mill

      2/26/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by National Vision Holdings Inc.

      10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

      5/8/25 8:36:28 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      5/7/25 6:05:18 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by National Vision Holdings Inc.

      DEF 14A - National Vision Holdings, Inc. (0001710155) (Filer)

      4/29/25 6:22:58 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/14/24 12:33:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/12/24 4:45:48 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/4/24 1:18:26 PM ET
      $EYE
      Ophthalmic Goods
      Health Care